Background: Breast cancer stem cells with a CD44(+)CD24(-) phenotype are the origin of breast tumors. Strong CD44 expression in this population indicates its important role in maintaining the stem cell phenotype. Previous studies show that CD44 down-regulation causes CD44(+)CD24(-) breast cancer stem cells to differentiate into non-stem cells that are sensitive to antitumor drugs and lose many characteristics of the original cells. In this study, we determined tumor suppression in non-obese severe combined immunodeficiency mice using CD44 shRNA therapy combined with doxorubicin treatment.
Methods: Tumor-bearing non-obese severe combined immunodeficiency mice were established by injection of CD44(+)CD24(-) cells. To track CD44(+)CD24(-) cells, green fluorescence protein was stably transduced using a lentiviral vector prior to injection into mice. The amount of CD44 shRNA lentiviral vector used for transduction was based on CD44 down-regulation by in vitro CD44 shRNA transduction. Mice were treated with direct injection of CD44 shRNA lentiviral vector into tumors followed by doxorubicin administration after 48 hours. The effect was evaluated by changes in the size and weight of tumors compared with that of the control.
Results: The combination of CD44 down-regulation and doxorubicin strongly suppressed tumor growth with significant differences in tumor sizes and weights compared with that of CD44 down-regulation or doxorubicin treatment alone. In the combination of CD44 down-regulation and doxorubicin group, the tumor weight was significantly decreased by 4.38-fold compared with that of the control group.
Conclusion: These results support a new strategy for breast cancer treatment by combining gene therapy with chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358118 | PMC |
| http://dx.doi.org/10.2147/OTT.S30609 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Doubly self-assembled dermatan sulfate/chitosan nanoparticles for targeted siRNA delivery in cancer therapy.
J Colloid Interface Sci
February 2025
Laboratory of Pharmaceutical Nanomaterials Science, Department of Materials Science and Engineering Technion - Israel Institute of Technology, Technion City 320003, Haifa, Israel. Electronic address:
RNA interference, a naturally occurring regulatory mechanism in which small interfering RNA (siRNA) molecules are responsible for the sequence-specific suppression of gene expression, emerged as one of the most promising gene therapies in cancer. In this work, we investigate a microfluidics double self-assembly method based on micellization and polyelectrolyte complex formation for the encapsulation of siRNA targeting the BIRC5 gene, a member of the inhibitor of apoptosis gene family, that codes for survivin a protein of theinhibitorof apoptosis protein family that is involved in triple-negative breast cancer (TNBC) proliferation and metastasis within nanoparticles of an amphiphilic chitosan-graft-poly(methyl methacrylate) copolymer and low-molecular weight dermatan sulfate, a polysaccharide targeting the CD44 receptor overexpressed in this tumor. Nanoparticles are spherical and display a hydrodynamic diameter of ∼ 200 nm, as measured by dynamic light scattering and scanning electron microscopy.
View Article and Find Full Text PDFCyclophilin A knockdown inhibits the proliferation and metastatic ability of AGS gastric cancer stem cells by downregulating CD147/STAT3/AKT/ERK and epithelial‑mesenchymal transition.
Mol Med Rep
January 2025
Department of Life Science and Biochemical Engineering, Graduate School, Sun Moon University, Asan, Chungcheongnam 31460, Republic of Korea.
Gastric cancer stem cells (GCSCs) contribute to the challenging aspects of gastric cancer, such as progression, metastasis, treatment resistance and recurrence. Inhibitors targeting cyclophilin A (CypA) have shown potential in curtailing GCSC growth. Building upon this, the current study delved deeper into understanding the functional role of CypA in controlling the proliferation and metastatic capabilities of GCSCs, employing CypA‑specific small interfering RNA.
View Article and Find Full Text PDFHyaluronic acid-functionalized MOFs for combined sunitinib and siRNA therapy in renal cell carcinoma.
Int J Biol Macromol
December 2024
Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110011, Liaoning, China. Electronic address:
Sunitinib is a first-line treatment for renal cell carcinoma (RCC), but suffers from drug resistance, causing therapy failure. Therefore, nano-scale delivery systems should be introduced for targeted delivery. Metal-organic frameworks (MOFs) are attractive drug carriers that not only enable multidrug combination therapies but also exert photodynamic effects by incorporating photosensitizers as components.
View Article and Find Full Text PDFTargeting Hypoxia-Inducible Factor-1α in Pancreatic Cancer: siRNA Delivery Using Hyaluronic Acid-Displaying Nanoparticles.
Pharmaceutics
September 2024
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield M13 9PT, UK.
Conventional anticancer therapies often lack specificity, targeting both cancerous and normal cells, which reduces efficacy and leads to undesired off-target effects. An additional challenge is the presence of hypoxic regions in tumors, where the Hypoxia Inducible Factor (HIF) transcriptional system drives the expression of pro-survival and drug resistance genes, leading to radio- and chemo-resistance. This study aims to explore the efficacy of targeted nanoparticle (NP)-based small interfering RNA (siRNA) therapies in downregulating these genes to enhance treatment outcomes in pancreatic cancer, a tumor type characterized by high CD44 expression and hypoxia.
View Article and Find Full Text PDFTGM2-Mediated Autophagy Contributes to the Radio-Resistance of Non-Small Cell Lung Cancer Stem-like Cells.
Biomedicines
September 2024
The First School of Clinical Medicine, Lanzhou University, Lanzhou 730030, China.
Article Synopsis
- Cancer stem-like cells (CSCs) show a resistance to radiation therapy, and this study focused on understanding the differences in radiation sensitivity between standard A549 cells and CD44A549 stem-like cells, using X-rays and carbon ion radiation.
- The research involved various techniques—including animal experiments, assays, and mass spectrometry—to evaluate cell viability, metabolic differences, and autophagy activity, which played a role in the observed radio-resistance.
- Key findings identified TGM2 as an important factor in radio-resistance, suggesting that the CD44-TGM2-LC3 signaling pathway could be targeted to enhance the effectiveness of treatments against CSCs in non-small cell lung cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!